Likewise,Hecker et al. (11) demonstrated that IFN-ß therapy for atleast one year did not normalize the aberrant expressionof some miRNAs such as miR-326 which is differentiallyexpressed in MS. This evidence concerns the gene IFNA1 and myeloid sarcoma.